Uniqure NV's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 104 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.62.In the medium term, the stock price is expected to trend up.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Media Coverage